Crinetics Pharmaceuticals Appoints New Auditor Following Dismissal of BDO USA

Details

announced the dismissal of BDO USA, P.C. as its independent registered public accounting firm, effective immediately. The decision was made by the Audit Committee of the Board of Directors. BDO's reports on the Company's consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 did not contain any adverse opinions, disclaimers, or qualifications. In place of BDO, the Company has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no disagreements with BDO on accounting principles, financial statement disclosure, or auditing procedures, and no reportable events occurred during the engagements.

Items reported

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.